Iriana Sadaghiani
Family · Clovis, CANPI 1669985974
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.9% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $524 and has fallen 96.0% since, to $21 in 2025.
Across 40 payments — averaging $22.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacyclics LLC, An Abbvie Company$198
- GSK$184
- Takeda Pharmaceuticals U.S.A., Inc.$91
- Daiichi Sankyo Inc.$53
- AbbVie$51
- Novartis$43
- plus $299 from 16 others
What the payments were for
- Food & beverage$85493%
- Education$657%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | 9 | $198 |
| GSK | 3 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $91 |
| Daiichi Sankyo Inc. | 3 | $53 |
| AbbVie | 2 | $51 |
| Novartis | 2 | $43 |
| EMD Serono, Inc. | 2 | $42 |
| Beigene USA, Inc. | 2 | $29 |
| Sobi, Inc | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
| Amgen | 1 | $18 |
| Sanofi | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Acrotech Biopharma Inc. | 1 | $16 |
| Heron Therapeutics, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Seagen Inc. | 1 | $13 |
| Myovant Sciences Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEJULA$125
How this compares
$919 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 11 | $895 |
| Anastrozole | 30 | $851 |
| Letrozole | 11 | $205 |
Paid to pharmacies, not to this prescriber.
Other family in Clovis
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.